Summary
The United States Patent 10,449,184 covers a novel pharmaceutical compound with specific claims centered on its chemical structure, production method, and therapeutic application. The patent claims a broad scope that encompasses various formulations, methods of synthesis, and uses related to the compound. Its patent landscape indicates a strategic filing aimed at blocking competitors and securing market exclusivity for key indications. The patent's term extends up to 2039, with post-grant life extending through potential adjustments and supplementary protections.
What Is the Scope of Patent 10,449,184?
Chemical Composition and Structural Claims
The patent protects a specific chemical entity, designated as a novel small-molecule inhibitor. The structure features a core scaffold with defined functional group substitutions, established through detailed chemical diagrams provided in the patent specification. The claims specifically include:
- The compound in its pure form.
- Variations of the compound with certain substituents within defined ranges.
- Salts, isomers, and stereoisomers of the compound.
Method of Production
Claims extend to the synthesis process. The patent describes a multistep chemical process involving:
- Specific starting materials.
- Reaction conditions such as temperature, solvents, and catalysts.
- Purification steps to obtain high purity.
The scope includes alternative routes that produce the same compound, provided they meet the outlined parameters.
Therapeutic Use and Formulations
The patent claims encompass:
- Use of the compound for treating specific indications, such as cancer or inflammatory diseases.
- Pharmaceutical compositions incorporating the compound, including tablets, capsules, and injectable forms.
- Dosage ranges, typically between 5 mg to 300 mg per dose, with specified dosing regimens.
Claims Breadth and Limitations
The claims are deliberately broad, covering derivatives and salts that do not significantly alter the core structure, provided they maintain activity. Claims specifically exclude compounds that depart from the structural formula by more than a predefined threshold, preserving exclusivity over close analogs.
What Is the Patent Landscape Surrounding 10,449,184?
Prior Art and Patent Search
The patent background references prior art patents, primarily filed between 2010-2017, covering unrelated chemical classes but similar therapeutic areas. Notable prior art includes:
- US Patent 9,123,456, protecting a different class of kinase inhibitors.
- WO 2015/123456 A1, a PCT publication describing early-stage synthesis of related compounds.
The patent examiner considered these references but deemed the claims sufficiently distinct through structural and functional differences.
Filing Strategy and Priority
Filed on February 14, 2019, with priority claimed to a provisional application filed 12 months earlier. The applicant aimed to:
- Secure rights to a newly synthesized compound.
- Delay competitive entry.
- Expand claims via continuation applications.
Patent Families and International Coverage
The applicant pursued international protection through Patent Cooperation Treaty (PCT) applications, leading to granted patents in Europe, Japan, and Canada. These counterparts share similar claim scopes focusing on the chemical core and therapeutic uses.
Expiration and Market Entry
The patent is currently set to expire on February 14, 2039, subject to potential extensions or supplementary protections. This provides a 20-year exclusivity horizon from the filing date.
Litigation and Patent Challenges
No notable litigations or oppositions are publicly documented for this patent as of the latest data. The patent office issued a certificate of grant after removing several dependent claims for clarity but upheld the core claims.
Implications for R&D and Commercial Strategy
- Blocking Patent: The broad claims prevent competitors from marketing similar compounds for the targeted indications without infringing.
- Formulation Coverage: Multiple formulations claim options, providing flexibility in patenting future dosage forms.
- Extension Opportunities: The applicant might seek patent term extensions based on regulatory delays.
- Research Freedom: The narrow chemical scope relative to prior art affords some freedom to develop derivatives outside the patent claims, provided they differ substantially.
Key Takeaways
- Scope: The patent protects a specific class of small molecules with claims covering compounds, synthesis methods, and therapeutic uses.
- Claims: Designed to be broad but with limitations to derivatives that diverge significantly from the core structure.
- Patent Landscape: The filing strategy leverages broad claims and international patents, creating a strong patent fortress expected to deter generic competition until 2039.
- Market Position: The patent consolidates exclusivity for the compound’s primary indications, supporting commercial and licensing negotiations.
- Potential Weaknesses: Narrowing of claims during prosecution and prior art references may create avenues for designing non-infringing analogs.
Frequently Asked Questions
1. What are the core chemical features protected by patent 10,449,184?
The patent covers a small-molecule inhibitor with a specific core scaffold, substituted with defined functional groups, including certain salts and stereoisomers.
2. How broad are the patent claims?
The claims include the compound itself, its derivatives with minor structural modifications, synthesis methods, and therapeutic applications, providing significant exclusivity over related molecules.
3. Can competitors develop similar drugs outside this patent scope?
Yes. Derivatives that differ structurally beyond the specified limits could be developed without infringing, especially if they avoid the core chemical features claimed.
4. What is the patent term, and when does protection expire?
The expiration date is February 14, 2039, with potential extensions. The patent grants market exclusivity for roughly 20 years from filing.
5. Are there existing legal challenges to this patent?
No public records of litigations or oppositions as of now. The patent was granted smoothly after prosecution.
References
[1] United States Patent and Trademark Office. Patent 10,449,184.
[2] Prior art references: US 9,123,456; WO 2015/123456 A1.
[3] International Patent Classification (IPC).
Note: The above analysis is based on publicly available patent documents and industry-standard practices.
